分享
分销 收藏 举报 申诉 / 28

类型心血管疾病中药材循证应用的进展-英文.ppt

  • 上传人:知****运
  • 文档编号:14648168
  • 上传时间:2026-10-25
  • 格式:PPT
  • 页数:28
  • 大小:1.47MB
  • 下载积分:10 金币
  • 配套讲稿:

    如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。

    特殊限制:

    部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。

    关 键  词:
    心血管疾病 中药材 应用 进展 英文
    资源描述:
    Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,*,*,RMIT University,10,th,SCICC,Guangzhou,China,2008,Recent Progress in the Evidence-Based Application of Herbal Medicines for Cardiovascular Diseases,Professor Shufeng Zhou,MD,PhD,School of Health Sciences,WHO Collaborating Center for Traditional Medicine,RMIT University,Bundoora,Victoria 3083,Australia,Phone:,Tel:+61 3 9925 7794;Fax:+61 3 9925 7178,Email:,shufeng.,11 April 2008,An Overview of Global Herbal Use,All folk medicine includes the use of plant products.,11,145 species of herbal plants worldwide;534 species of plants for Chinese Medicine.,WHO definition botanical origin,without adulteration of any synthetic drugs.,Legal status:food supplements(,FDA&TGA,),“DSHEA”;drugs/health foods(,SFDA of China,).,US$25 billion;market value,10,15%/per year.,2 billion in Australia.,40%Caucasian and 80%Asians use or used herbs.,Active,Components,Biotransformation,Excretion,Absorption,Response/Toxicity,?,?,?,?,Preclinical Stage,Phase I,Phase II,Phase III,Phase IV,Clinical Trials of Herbal Medicines,General acceptance of humans,Safety and Efficacy,More data on safety and Efficacy,Herbs,PK,PD,Pharmacokinetics of,TPNS,formula in stroked patients,OMEGA,FINAL ESTIMATE,RSE(%),95%CONFIDENCE INTERVAL,CV(%),LBOUND,UBOUND,1,,,1,0.132,30.2,0.054,0.210,36.3,2,,,2,0.0318,46.5,0.00279,0.0608,17.8,3,,,3,0.0001,.,.,.,1.00,4,,,4,0.363,47.5,0.0249,0.703,60.3,RESIDUAL VARIABILITY(SIGMA,;,CV%if proportional,S.D.if additive),1,,,1,0.00752,39.6,0.00168,0.0134,8.67,2,,,2,1.00e-005,.,.,.,SD=0.00316,Injection rate(mg/min),PT,TT,Fib,APTT,Integrated Conc.(g/ml),PT,PT,TT,Fib,APTT,Herbal medicines as multi-component therapeutics,It is possible to integrate PK and PD for herbal medicines.,Challenges:multi-component therapeutics?,Which marker compounds to measure?,How to determine therapeutic window?,Types of Clinical Reports on Herb-Drug Interactions,N=85,What Herbs Interact with Drugs?,N=85,Herb,Interacting drugs,Danggui,Warfarin,Danshen,Warfarin,Garlic,Saquinavir,ritonavir,warfarin,chlorpropamide,Ginkgo,Trazodone,warfarin,digoxin,Ginseng,Alcohol,phenelzine,warfarin,Hawthorn,Digoxin(,no change,),Kava,Alcohol,alprazolam,bromazepam,L-dopa,Milk thistle,Indinavir,Piperine,Propranolol,rifampin,sparteine,theophylline,phenytoin,Toxicity due to Herb-Drug Interactions,Herb+Drug,Toxicity,SJW+cyclosporine A,Organ rejection,SJW+oral contraceptives,Breakthrough bleeding&unplanned pregnancies,Garlic+chlorpropamide,Hypoglycemia,Kava+alprazolam,Semicoma,Kava+L-dopa,“Off”periods in Parkinson disease,Ginseng+phenelzine,Mania,Ginkgo+trazodone,Coma,Ginkgo+warfarin/aspirin,Bleeding,Danshen+warfarin,Bleeding,SJW-Drug Interactions,Antidepressants:,amitriptyline,;,SSRIs,(,sertraline,Zoloft),Anticancer drug:irinotecan(CPT-11),Anticoagulants:warfarin(,coumadin,),phenprocoumon,Antihistamine:,fexofenadine,Anti-HIV agents:PI:indinavir;,RTI:nevirapine,Bronchodilator:theophylline,Hypoglycemics,:,tolbutamide,Cardiovascualr,drugs:digoxin,simvastatin,Opiates:methadone,loperamide,Oral contraceptives,Sedatives:,alprazolam,&midazolam,Immunosuppressants:c,yclosporine,&t,acrolimus,Mechanisms for Herb-Drug Interactions,Drug Response,Metabolizing enzymes,(CYPs),Identical Targets,Transporters,(PgP),Different Targets,Pharmacokinetics(PK),Pharmacodynamics(PD),Herb-PgP Interactions,Herb,Modulation of PgP,Curcumin,inhibition,Hawthorn,?,Garlic,Inhibition,Ginseng,Mostly inhibition,Green tea,Inhibition,Milk thistle,Inhibition,Piperine,Inhibition,SJW,Induction,Rosemary,Inhibition,Acknowledgment,s,Prof.Guangji Wang,Prof.,Xiyong,Yu,Prof.Charlie Xue and,Chunguang,Li,Prof.Eli Chan,Prof.,Wen,Xie,Prof.Tony,Koon,Prof.James W Paxton&Bruce,Baguley,Prof.John O Miners,Prof.Ronald G Dickinson,Prof.,Min Huang&,Anlong,Xu,Prof.Wei,Duan,Prof.,Xiaotian,Lee,Prof.,Ge,Lin,Prof.,Qiang,Zhang,Prof.Yi-,Zhun,Zhu,National University of Singapore Academic Research Funds,Singapore Cancer Syndicate,RMIT University Grant for New Institute,NICM,grant of Australia,Auckland Medical Research Foundation,New Zealand Cancer Society Funds,Maurice&Phyllis,Paykel,Trust,Hu,Zeping,Tian Quan,Zhang Jing,Sun,Zhuming,Sun,Feng,Zhang,Yaochung,Linlin,Wang,Meredith Payne,Liping,Yang,Vivian Chan,Yuan Ming Di,Yanli,Zhou,PhD students,Dr,Xiaoxia,Yang,Dr,Gui,Jingang,Postdoc fellows,
    展开阅读全文

    开通VIP折扣优惠下载文档

    提示  咨信网声明:本文档由用户上传并分享,仅供学习交流、研究之用,未经授权,严禁复制、发行、汇编、翻译或网络传播等,侵权必究。

    咨信网小贴示:
    1、浏览或下载可查看了解,请点击【咨信网告知】。
    2、下载文件中如有侵权或不适当内容,将立即纠正。
    3、如果因为网速或其他原因下载失败请重新下载,重复下载[60天内]不扣币。
    4、开具发票登录电脑端申请,请点击【索取发票】。

    咨信网客服组:【微信客服】

    自信AI创作助手
    关于本文
    本文标题:心血管疾病中药材循证应用的进展-英文.ppt
    链接地址:https://www.zixin.com.cn/doc/14648168.html

    Copyright ©2010-2026   All Rights Reserved  宁波自信网络信息技术有限公司 版权所有   |  客服电话:0574-28810668    微信客服:咨信网客服    投诉电话:18658249818   

    违法和不良信息举报邮箱:help@zixin.com.cn    文档合作和网站合作邮箱:fuwu@zixin.com.cn    意见反馈和侵权处理邮箱:1219186828@qq.com   | 证照中心

    12321jubao.png12321网络举报中心 电话:010-12321  jubao.png中国互联网举报中心 电话:12377   gongan.png浙公网安备33021202000488号  icp.png浙ICP备2021020529号-1 浙B2-20240490   


    关注我们 :微信公众号  抖音  微博  LOFTER               

    自信网络  |  ZixinNetwork